[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital, Martin\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":207},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,72,98,122,149,174],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100637891","active-versus-passive-anal-sphincter-training-in-patients-with-fecal-incontinence-100637891",false,"NCT07604415","Active Versus Passive Anal Sphincter Training in Patients With Fecal Incontinence","ACTIPAST","Inclusion Criteria:\n\n* Signed informed consent\n* Age ≥18 years\n* Diagnosis of fecal incontinence (urge, passive, or mixed type) with at least 1 episode of involuntary stool leakage requiring hygiene intervention or underwear change per month for ≥3 months\n* Vaizey (St. Mark's) Incontinence Score ≥8\n* Ability to understand study procedures and comply with the 12-week home intervention\n* Willingness to attend all study visits and assessments\n* Stable medical management for fecal incontinence for at least 4 weeks prior to enrollment\n\nExclusion Criteria:\n\n* Complete spinal cord injury above the conus medullaris\n* Active inflammatory bowel disease flare requiring systemic therapy or not in clinical remission\n* Rectal prolapse requiring surgical intervention\n* Severe symptomatic hemorrhoids interfering with anorectal assessments or device use\n* Active anal fissure or perianal fistula\n* Active colorectal cancer or history of colorectal cancer within 5 years\n* Colorectal surgery within the previous 6 months\n* Pregnancy or planned pregnancy during study participation\n* Implanted cardiac pacemaker or defibrillator\n* Other implanted electrical devices contraindicating electrical stimulation\n* Previous specialized pelvic floor physiotherapy, biofeedback therapy, EMG-guided rehabilitation, or anal electrical stimulation within 3 months prior to randomization\n* Cognitive impairment preventing understanding of study procedures or informed consent\n* Uncontrolled severe diarrhea (\\>5 liquid stools\u002Fday)\n* Anal stenosis preventing probe insertion\n* Severe anal sphincter defect (\\>120° on ultrasound) requiring surgical repair\n* Isolated severe rectal sensory dysfunction without significant sphincter dysfunction\n* Previous pelvic radiotherapy\n* Concurrent participation in another interventional clinical trial","ALL","18 Years",{"count":19,"type":20},24,"ESTIMATED","INTERVENTIONAL",[23],"NA","Fecal incontinence is a disabling condition that can substantially impair quality of life. This study evaluates whether home-based anal electrical stimulation combined with active voluntary anal sphincter contraction is superior to electrical stimulation alone in patients with fecal incontinence.\n\nThe study is a prospective, randomized, parallel-group, open-label controlled trial. Participants will be randomized in a 1:1 ratio to either electrical stimulation with synchronized active sphincter contraction or electrical stimulation alone. The primary outcome is the change in Vaizey\u002FSt. Mark's Incontinence Score from baseline to week 12. Secondary outcomes include fecal incontinence episodes, quality of life, anorectal manometry parameters, adherence, safety, and sustained response during follow-up.",[26],"Fecal Incontinence",[28,29,30],"fecal incontinence","anal stimulation","pelvic floor training","RECRUITING","2026-05-22",{"date":34,"type":35},"2026-05-28","ACTUAL",{"date":37,"type":35},"2026-05-15",{"date":39,"type":20},"2029-05",{"name":41,"class":42},"University Hospital, Martin","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":43},"100636040","assessment-of-digital-technologies-for-detection-of-dental-caries-100636040","NCT07560514","Assessment of Digital Technologies for Detection of Dental Caries","Assessment and Comparison of Diagnostic Technologies for the Detection of Dental Caries in Clinical Practice","Inclusion Criteria:\n\n* Age 18-65 years\n* Presence of permanent dentition only\n* Presence of primary or secondary carious lesions\n* Presence of all teeth in the lateral segment (teeth 4-7) in both maxilla and mandible\n* Signed informed consent including agreement with photodocumentation, bitewing radiographs, and use of AI-based diagnostic methods (including DIAGNOcam)\n\nExclusion Criteria:\n\n* Age under 18 or over 65 years\n* Extensive crown destruction affecting more than two-thirds of the tooth\n* Carious lesions reaching the dental pulp or threatening pulp vitality\n* Inability or refusal to undergo radiographic examination (bitewing radiographs)\n* Teeth with fixed prosthetic restorations in the examined area Refusal to participate or to use AI-based diagnostic methods (including DIAGNOcam)",true,"65 Years",{"count":54,"type":20},100,[23],"This study aims to evaluate and compare different digital diagnostic technologies used for the detection of dental caries in clinical practice. The study focuses on assessing the diagnostic accuracy of various methods, including visual examination and digital diagnostic tools, in identifying dental caries in patients. The results will contribute to improving early detection and diagnostic strategies in dentistry.",[58],"Dental Caries",[60,61,62,63],"dental caries","caries detection","digital technology","artificial intelligence","2026-04-27",{"date":66,"type":35},"2026-05-01",{"date":68,"type":35},"2025-11-30",{"date":70,"type":20},"2026-08",{"name":41,"class":42},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":43},"100619000","physical-performance-assessment-in-kidney-transplant-evaluation-100619000","NCT07338929","Physical Performance Assessment in Kidney Transplant Evaluation","Physical Performance Assessment in Kidney Transplant Evaluation Using the Short Physical Performance Battery (SPPB)","FRAIL-KTx","Inclusion Criteria:\n\n1. Adult patients (≥18 years) undergoing evaluation for kidney transplantation.\n2. Patients on dialysis.\n3. Ability and consent to participate.\n\nExclusion Criteria:\n\n1. Non-adult patients.\n2. Patients unable to provide informed consent.\n3. Acute medical conditions prohibiting SPPB assessment.",{"count":81,"type":20},50,"OBSERVATIONAL","This prospective cohort study investigates physical frailty, assessed by the Short Physical Performance Battery (SPPB), in patients evaluated for kidney transplantation. The study aims to compare SPPB scores before listing, annually during the waiting period, and after transplantation at 6 and 12 months. It also includes a control group of dialysis patients not eligible for transplantation to evaluate differences in physical performance. The goal is to understand how frailty impacts transplant outcomes and patient recovery.",[85],"Frailty Syndrome",[87,88,89],"kidney transplantation","chronic kidney diseases","frailty","2026-01-06",{"date":92,"type":35},"2026-01-14",{"date":94,"type":35},"2025-10-01",{"date":96,"type":20},"2028-10-31",{"name":41,"class":42},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":106,"conditions":107,"keywords":110,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":43},"100614126","platelet-aggregation-in-the-diagnosis-of-acute-graft-rejection-100614126","NCT07275541","Platelet Aggregation in the Diagnosis of Acute Graft Rejection","Inclusion Criteria:\n\n* adult patients (≥18 years)\n* primary kidney transplantation\n* living \u002F deceased donor kidney transplantation\n* ability and consent to participate\n\nExclusion Criteria:\n\n* non-adult patients\n* secondary \u002F tertiary kidney transplantation\n* antiplatelet therapy\n* patients unable to provide informed consent",{"count":105,"type":20},60,"The study titled \"Platelet Aggregation in the Diagnosis of Acute Graft Rejection\" is a pilot observational study evaluating whether alterations in platelet function can serve as non-invasive markers of acute rejection in kidney transplant recipients. Platelet aggregation is assessed using optical aggregometry, flow-cytometric P-selectin (CD62-P) expression, and soluble P-selectin levels before kidney transplantation and at the time of protocol biopsies performed at 3 and 12 months after kidney transplantation. Patients with suspected graft dysfunction undergoing indication biopsy are also included. Platelet activation markers are correlated with histopathological findings, donor-specific antibodies, metabolic parameters, and clinical outcomes. The goal is to determine whether platelet activation profiles can identify acute cellular or antibody-mediated rejection and contribute to the development of a non-invasive diagnostic tool.",[108,109],"Platelet Aggregation","Kidney Transplant Rejection",[87,111,112,113],"platelet aggregation","acute rejection","non-invasive marker","2025-11-27",{"date":116,"type":35},"2025-12-10",{"date":118,"type":35},"2024-11-26",{"date":120,"type":20},"2027-11-26",{"name":41,"class":42},{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":21,"phases":132,"briefSummary":133,"conditions":134,"keywords":137,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":43},"100599179","daratumumab-for-late-antibody-mediated-rejection-100599179","NCT07081126","Daratumumab for Late Antibody-Mediated Rejection","Daratumumab for Late Antibody-Mediated Rejection in Kidney Transplant Recipients With De Novo Donor-Specific Antibodies: A Case-Control Study","DARTABMR","Inclusion Criteria:\n\n* Kidney transplant recipient (first or subsequent transplant)\n* Diagnosis of late ABMR (diagnosed \\>12 months post-transplant)\n* Biopsy-proven ABMR\n* Presence of de novo DSA\n\nExclusion Criteria:\n\n* Active infection\n* Other significant comorbidities that could affect outcomes or treatment safety\n* Contraindications to daratumumab\n* Prior treatment with daratumumab\n* Specific types of DSA (consider specifying, e.g., unacceptable antigens)\n* Non-adherence to standardized immunosuppression protocol (tacrolimus, MMF, steroids)\n* iFTA 2 or 3 on baseline biopsy",{"count":131,"type":20},20,[23],"The study titled \"Daratumumab for Late Antibody-Mediated Rejection in Kidney Transplant Recipients with De Novo Donor-Specific Antibodies\" (DARTABMR) is a case-control investigation assessing whether daratumumab is more effective than standard therapies (such as IVIG, plasmapheresis, and rituximab) in treating late antibody-mediated rejection (ABMR) in kidney transplant patients with new donor-specific antibodies (DSA). The research compares outcomes like kidney function stabilization, DSA reduction, and biopsy improvements between patients receiving daratumumab and those on standard treatments. Participants include transplant recipients diagnosed with ABMR more than 12 months post-transplant, with data collected on clinical, immunological, and biopsy parameters before, during, and after treatment. The study emphasizes matching participants based on key variables to minimize bias and will analyze treatment success rates, changes in kidney function and DSA levels, and adverse events.",[135,136],"Kidney Tansplant","Acute Rejection (AR) of Transplanted Kidney",[138,139,140],"daratumumab","kidney transplant","acute antibody mediated rejection","2025-07-15",{"date":143,"type":35},"2025-07-23",{"date":145,"type":35},"2025-07-01",{"date":147,"type":20},"2026-12-31",{"name":41,"class":42},{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":158,"conditions":159,"keywords":162,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":173},"100597245","predicting-outcomes-in-posttransplant-diabetes-mellitus-via-microrna-100597245","NCT07055984","Predicting Outcomes in Posttransplant Diabetes Mellitus Via microRNA","POD-MIR","Inclusion Criteria:\n\n* Adult patients undergoing kidney transplantation.\n* Absence of pre-existing type 1 or type 2 diabetes mellitus.\n* Willingness to provide informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n* Pre-existing type 1 or type 2 diabetes mellitus.\n* Previous organ transplantation.\n* Severe comorbidities that could confound the assessment of PTDM (e.g., pancreatic disease).\n* Inability to provide informed consent.",{"count":157,"type":20},130,"The study aims to improve the prediction and early detection of post-transplant diabetes mellitus (PTDM) in kidney transplant recipients. The investigators are investigating whether specific microRNA profiles measured 3 months after transplantation can reliably predict the development of PTDM within the following one to two years.\n\nAdditionally, the investigators are evaluating how traditional risk factors-such as age, immunosuppressive therapy, obesity, and infections like CMV-interact with these microRNA markers.\n\nThe ultimate goal of this research is to identify early indicators of blood sugar issues, enabling timely interventions to improve health outcomes and personalize patient care after kidney transplantation.",[160,161],"Diabetes Mellitus","Kidney Transplant",[163,164,87],"post-transplant diabetes mellitus","microRNA","2025-06-27",{"date":167,"type":35},"2025-07-09",{"date":169,"type":35},"2025-04-28",{"date":171,"type":20},"2029-04-28",{"name":41,"class":42},2,{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":21,"phases":183,"briefSummary":184,"conditions":185,"keywords":192,"overallStatus":198,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":43},"100587534","amino-acid-infusion-in-kidney-transplant-recipients-100587534","NCT06929637","Amino Acid Infusion in Kidney Transplant Recipients","The Effect of Amino Acid Infusion on Early Graft Function After Kidney Transplantation","AID-KT","Inclusion Criteria:\n\n* Adult patients (≥18 years) undergoing deceased or living donor kidney transplantation\n* First-time kidney transplant recipients\n* No known allergy or contraindication to amino acids\n* Stable hemodynamic status post-transplant\n* Signed informed consent\n\nExclusion Criteria:\n\n* Patients requiring immediate dialysis post-transplant\n* Multi-organ transplant recipients\n* Severe hepatic dysfunction (Child-Pugh C)\n* Uncontrolled infection or sepsis\n* Malignancy within the past 5 years (except non-melanoma skin cancer)\n* Prior participation in conflicting clinical trials",{"count":54,"type":20},[23],"The study addresses the impact of amino acid infusion in the early post-transplant period on graft function and the incidence of post-transplant complications.",[186,187,188,189,190,191],"Short-term Graft Function","Metabolic Effects","Nutritional Effect","Immunological &Amp; Inflammatory Markers","Safety","Adverse Events",[87,193,194,195,196,197],"aminoacids","delayed graft function","diabetes mellitus","acute graft rejection","estimated glomerular filtration rate","NOT_YET_RECRUITING","2025-04-08",{"date":201,"type":35},"2025-04-16",{"date":203,"type":20},"2025-09-15",{"date":205,"type":20},"2029-01-01",{"name":41,"class":42},""]